Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3164
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Antonio, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 541–552 of 3,164 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Recruiting No phase listed Observational

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT06564974
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Not yet recruiting Early Phase 1 Interventional

Radiographic Changes in the Maxillary Sinus Following Closed Sinus Augmentation With Leukocyte Platelet Rich Fibrin

NCT07836725
View directory record Official record
Conditions
Partially Edentulous Maxilla
Interventions
Leukocyte Platelet Rich Fibrin
Biological
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Recruiting Phase 2 Interventional

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

NCT04684368
View directory record Official record
Conditions
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions
Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

NCT06745947
View directory record Official record
Conditions
HIV Prevention
Interventions
EFT
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Active, not recruiting Phase 3 Interventional

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]

NCT04742777
View directory record Official record
Conditions
Aging
Interventions
rapamycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
70 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Recruiting Phase 1 Interventional

SLV-154 Treatment of Advanced Cancers

NCT06771219
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Interventions
SLV-154
Drug
Lead sponsor
Solve Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Newport Beach, California • St Louis, Missouri • East Brunswick, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Active, not recruiting Not applicable Interventional

Chronic Pain Management In Primary Care Using Behavioral Health Consultants

NCT04680000
View directory record Official record
Conditions
Chronic Pain
Interventions
Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP), BCBT-CP Booster
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Completed Phase 2 Interventional

NE3107 in Adults With Neurological Symptoms of Long COVID

NCT06847191
View directory record Official record
Conditions
Long COVID
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 15, 2026, 6:09 AM EST
Recruiting Phase 1Phase 2 Interventional

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Elironrasib, Daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Duarte, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 15, 2026, 6:09 AM EST